Cancer stem cells: Implications for the progression and treatment of metastatic disease: Stem Cells Review Series

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 2, 2008, Pages 374-390

  Croker, A K ^a   Allan, A L ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Cancer stem cell (CSC); CD133; CD44; Metastasis; Metastatic ineffiiency; Metastatic niche; Resistance to therapy; SDF 1 CXCR4 axis; Stem cell

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; GLYCOPROTEIN; HERMES ANTIGEN; LEUKOCYTE ANTIGEN; PEPTIDE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER STEM CELL; DISEASE COURSE; FORECASTING; HUMAN; METABOLISM; METASTASIS; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CHEMOKINE CXCL12; DISEASE PROGRESSION; FORECASTING; GLYCOPROTEINS; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PEPTIDES; RECEPTORS, CXCR4;

EID: 42349093952     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00211.x     Document Type: Article

References (108)

1. Canadian Cancer Statistics 2007. http://www.cancer.ca
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 57 : 43 66.
3. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 366 : 2087 106.
4. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001 358 : 277 86.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress-es HER2. N Engl J Med. 2001 344 : 783 92.
6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 355 : 2542 50.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 350 : 2335 42.
8. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 366 : 1527 37.
9. Pusztai L, Hortobagyi GN. High-dose chemotherapy: how resistant is breast cancer? Drug Resist Updat. 1998 1 : 62 72.
10. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002 2 : 563 72.
11. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004 4 : 448 56.
12. Weiss L. Metastatic inefficiency. Adv. Cancer Res. 1990 54 : 159 211.
13. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. Multistep nature of metastatic inefficiency:dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998 153 : 865 73.
14. Ewing J. A treatise on tumors. In : Neoplastic Diseases. London : W.B. Saunders Co 1928. pp. 77 89.
15. Paget S. The distribution of secondary growths in cancer of the breast (re-publication of the original 1889 Lancet article). Cancer Met Rev. 1989 8 : 98 101.
16. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am. 2001 10 : 257 69, vii-viii.
17. Weiss L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis. 1992 10 : 191 9.
18. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 2006 20 : 1915 24.
19. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms:pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005 23 : 879 94.
20. Smith MCP, Luker EK, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004 64 : 8604 12.
21. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002 2 : 442 54.
22. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007 369 : 1742 57.
23. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004 118 : 277 9.
24. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-β and the tumor microenvironment. J Cell Biochem. 2007 101 : 851 61.
25. Zavadil J, Cermak L, Soto-Nieves N, Bottinger E. Integration of TGF-β/Smad and Jagged1/Notch signaling in epithelial-to-mesenchymal transition. EMBO J. 2004 23 : 1155 65.
26. Moustakas A, Heldin C-H. Signaling networks guiding epithelial-mesenchyml transitions during embryo-genesis and cancer progression. Cancer Sci. 2007 98 : 1512 20.
27. Muller T, Bain G, Wang X, Papkoff J. Regulation of epithelial cell migration and tumor formation by β-catenin signaling. Exp Cell Res. 2002 280 : 119 33.
28. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 2007 3 : 7 17
29. PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cad-herin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006 10 : 437 49.
30. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res. 2005 65 : 11230 5.
31. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 414 : 105 11.
32. Virchow R. Editorial. Virchows Arch Pathol Anat Physiol Klin Med. 1855 3 : 23.
33. + stem cells identified in adult bone marrow. Leukemia. 2006 20 : 857 69.
34. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuris MA, Dick JE. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature. 1994 367 : 645 8.
35. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004 5 : 738 43.
36. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004 432 : 396 401.
37. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon caner cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007 445 : 106 10.
38. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003 100 : 3983 8.
39. + prostate cancer cells from xenografts human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006 25 : 1696 708.
40. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland MJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005 65 : 10946 51.
41. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007 67 : 1030 7.
42. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007 1 : 313 23.
43. Farnie G, Clarke RB. Mammary stem cells and breast cancer - role of notch signaling. Stem Cell Rev. 2007 3 : 169 75.
44. Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem. 2007 102 : 829 39.
45. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006 66 : 9339 44.
46. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004 23 : 7274 82.
47. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebrylskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast cancer heterogeneity. Cancer Cell. 2007 11 : 259 73.
48. Liu S, Dontu G, Mantle ID, Patel S, Ahn N-S, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006 66 : 6063 71.
49. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 2006 312 : 3701 10.
50. Hirschmann-Jax C, Fodter AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner M. A distinct "side population"of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004 101 : 14228 33.
51. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del Bo R, Strazzer S, Bresolini N, Comi GP. Identification of a primitive brain-derived neual stem cell population based on aldehyde dehydroge-nase activity. Stem Cells. 2006 24 : 975 85.
52. Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2007 26 : 87 98.
53. Li F, Tiede B, Massagué J, Kang Y. Beyond tumori-genesis: cancer stem cells in metastasis. Cell Res. 2007 17 : 3 14.
54. Spillane JB, Henderson MA. Cancer stem cells: a review. ANZ J Surg 2007 77 : 464 8.
55. Vaidya JS. An alternative model of cancer cell growth and metastasis. Int J Surg. 2007 5 : 73 5.
56. Kucia M, Ratajczak MZ. Stem cells as a two edged sword - from regeneration to tumor formation. J Physiol Pharmacol. 2006 57 : 5 16.
57. Scadden DT. The stem cell niche in health and leukemic disease. Clin Hematol. 2007 20 : 19 27.
58. Chepko G, Dickson RB. Ultrastructure of the putative stem cell niche in rat mammary epithelium. Tissue Cell. 2003 35 : 83 93.
59. Hendrix MJC, Seftor EA, Seftor REB, Kasemeier-Kulesa J, Kulesa PM, Postovit L-M. Reprogramming metastatic tumor cells with embryonic microenvironments. Nature. 2007 7 : 246 55.
60. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafil S, Lyden D. VEGFR1-positive haematopietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005 438 : 820 6.
61. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 2006 66 : 11089 93.
62. Psaila B, Kaplan RN, Port ER, Lyden D. Priming the 'soil' for breast cancer metastasis:the pre-metastatic niche. Breast Dis. 2006/2007 26 : 65 74.
63. Kaplan RN, Psaila B, Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med. 2006 13 : 72 81.
64. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007 449 : 557 65.
65. Erler JT, Bennewith KL, Nciolau M, Dornhofer N, Kong C, Le Q-T, Chi J-TA, Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006 440 : 1222 6.
66. Barnhart BC, Simon MC. Metastasis and stem cell pathways. Cancer Metastasis Rev. 2007 26 : 261 71.
67. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nature. 2007 7 : 429 40.
68. Politi K, Feirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Semin Cancer Biol. 2004 14 : 341 7.
69. Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, Pahanish P, Verma A. Transforming growth factor-β signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007 27 : 543 52.
70. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 2006 66 : 1883 90.
71. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006 66 : 4553 7.
72. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006 60 : 273 6.
73. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 2004 64 : 4302 8.
74. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003 100 : 13513 8.
75. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001 410 : 50 6.
76. Thayer SP, Pasca di Magliano M, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003 425 : 851 6.
77. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol. 2003 30 : 133 42.
78. Berman DM, Karhadkar SS, Maltra A, Montes de Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshieman JR, Watkins DN, Beachy PA. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003 425 : 846 51.
79. Park I-K, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest. 2004 113 : 175 9.
80. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003 3 : 895 902.
81. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005 5 : 275 84.
82. Dean M. Cancer Stem Cells: Redefining the Paradigm of Cancer Treatment Strategies. Mol Interv. 2006 6 : 140 8.
83. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002 99 : 507 12.
84. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K. The mul-tidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002 8 : 22 8.
85. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998 95 : 15665 70.
86. Cairns J. The cancer problem. Sci Am. 1975 233 : 64 72.
87. Cairns J. Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc Natl Acad Sci USA. 2002 99 : 10567 70.
88. Potten CS, Owen G, Booth D. Intestinal stem cells protect their genome by selective segregation of template DNA strands. J Cell Sci. 2002 115 : 2381 8.
89. Cai J, Weiss ML, Rao MS. In search of "stemness". Exp Hematol. 2004 32 : 585 98.
90. Park Y, Gerson SL. DNA repair defects in stem cell function and aging. Annu Rev Med. 2005 56 : 495 508.
91. + breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006 98 : 1777 85.
92. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 444 : 756 60.
93. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst. 2006 98 : 1755 7.
94. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007 7 : 791 8.
95. Smalley M, Ashworth A. Stem cells and breast cancer: A field in transit. Nat Rev Cancer. 2003 3 : 832 44.
96. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene. 2007 26 : 1357 60.
97. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004 431 : 707 12.
98. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999 397 : 164 8.
99. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006 12 : 1167 74.
100. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res. 2004 64 : 5702 11.
101. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther. 2001 90 : 105 56.
102. Sell S. Cancer stem cells and differentiation therapy. Tumour Biol. 2006 27 : 59 70.
103. Warrell RP Jr., de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993 329 : 177 89.
104. Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia. 1998 12 : 1866 80.
105. Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood. 2000 95 : 398 403.
106. Akashi K, He X, Chen J, Iwasaki H, Niu C, Steenhard B, Zhang J, Haug J, Li L. Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood. 2003 101 : 383 9.
107. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007 356 : 217 26.
108. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007 8 : 341 52.